Miriam Monge Joins Sartorius Stedim Biotech - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Miriam Monge Joins Sartorius Stedim Biotech


Sartorius Stedim Biotech (SSB), an international pharma and biotech supplier, introduced on Aug. 26 Miriam Monge as director of marketing for SSB’s integrated solutions unit. Monge will focus on sharpening SSB’s profile as an integrated solution provider for the biopharmaceutical industry.

Monge has more than 20 years of experience in the biopharmaceutical manufacturing sector and served as vice president of sales and marketing at Biopharm Services. She is a committee member of the International Society for Pharmaceutical Engineering and one of the founders of the Global Disposable Community of Practice. She regularly authors articles for technical bioprocess journals, analyzing the impact of disposable technologies on biomanufacturing.

Source: Sartorius Stedim Biotech

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here